Q Therapeutics, Inc. And Johns Hopkins University Researchers Collaborate on Study of Human Neural Glial Cells in Treatment of ALS

SALT LAKE CITY--(BUSINESS WIRE)--Q Therapeutics, Inc., announced today that studies are underway with Nicholas Maragakis, MD, and his research team at Johns Hopkins University to build on recent results showing that glial progenitor cells (GRPs) have a therapeutic benefit in a model of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease. Results of the initial Johns Hopkins studies appear this week in Nature Neuroscience.